{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T08:31:30Z","timestamp":1774686690389,"version":"3.50.1"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2008,4,22]],"date-time":"2008-04-22T00:00:00Z","timestamp":1208822400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nat Rev Cardiol"],"published-print":{"date-parts":[[2008,6]]},"DOI":"10.1038\/ncpcardio1191","type":"journal-article","created":{"date-parts":[[2008,4,22]],"date-time":"2008-04-22T20:04:00Z","timestamp":1208894640000},"page":"329-336","source":"Crossref","is-referenced-by-count":50,"title":["Spotlight on HDL-raising therapies: insights from the torcetrapib trials"],"prefix":"10.1038","volume":"5","author":[{"given":"Anatol","family":"Kontush","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maryse","family":"Gu\u00e9rin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M John","family":"Chapman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2008,4,22]]},"reference":[{"key":"BFncpcardio1191_CR1","doi-asserted-by":"publisher","first-page":"F56","DOI":"10.1093\/eurheartj\/sui044","volume":"7","author":"MJ Chapman","year":"2005","unstructured":"Chapman MJ (2005) Beyond LDL-cholesterol reduction: the way ahead in managing dyslipidaemia. Eur Heart J Suppl 7: F56\u2013F62","journal-title":"Eur Heart J Suppl"},{"key":"BFncpcardio1191_CR2","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1016\/S0140-6736(04)17018-9","volume":"364","author":"S Yusuf","year":"2004","unstructured":"Yusuf S  et al.; INTERHEART Study Investigators (2004) Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case\u2013control study. Lancet 364: 937\u2013952","journal-title":"Lancet"},{"key":"BFncpcardio1191_CR3","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1056\/NEJMoa064278","volume":"357","author":"P Barter","year":"2007","unstructured":"Barter P  et al.; Treating to New Targets Investigators (2007) HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med 357: 1301\u20131310","journal-title":"N Engl J Med"},{"key":"BFncpcardio1191_CR4","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1016\/j.numecd.2007.05.001","volume":"17","author":"SP Dullens","year":"2007","unstructured":"Dullens SP  et al. (2007) Increasing apoA-I production as a target for CHD risk reduction. Nutr Metab Cardiovasc Dis 17: 616\u2013628","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"BFncpcardio1191_CR5","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1124\/pr.58.3.1","volume":"3","author":"A Kontush","year":"2006","unstructured":"Kontush A and Chapman MJ (2006) Functionally defective HDL: a new therapeutic target at the crossroads of dyslipidemia, inflammation and atherosclerosis. Pharmacol Rev 3: 342\u2013374","journal-title":"Pharmacol Rev"},{"key":"BFncpcardio1191_CR6","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1038\/ncpcardio0500","volume":"3","author":"A Kontush","year":"2006","unstructured":"Kontush A and Chapman MJ (2006) Antiatherogenic small, dense HDL\u2014guardian angel of the arterial wall? Nat Clin Pract Cardiovasc Med 3: 144\u2013153","journal-title":"Nat Clin Pract Cardiovasc Med"},{"key":"BFncpcardio1191_CR7","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1097\/MOL.0b013e3282364a17","volume":"18","author":"BJ Ansell","year":"2007","unstructured":"Ansell BJ  et al. (2007) The paradox of dysfunctional high-density lipoprotein. Curr Opin Lipidol 18: 427\u2013434","journal-title":"Curr Opin Lipidol"},{"key":"BFncpcardio1191_CR8","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1097\/01.mol.0000236371.27508.d4","volume":"17","author":"M Navab","year":"2006","unstructured":"Navab M  et al. (2006) Potential clinical utility of high-density lipoprotein-mimetic peptides. Curr Opin Lipidol 17: 440\u2013444","journal-title":"Curr Opin Lipidol"},{"key":"BFncpcardio1191_CR9","doi-asserted-by":"publisher","first-page":"S62","DOI":"10.1016\/j.amjcard.2007.09.081","volume":"100","author":"PK Shah","year":"2007","unstructured":"Shah PK (2007) High-density lipoprotein mimetics: focus on synthetic high-density lipoprotein. Am J Cardiol 100: S62\u2013S67","journal-title":"Am J Cardiol"},{"key":"BFncpcardio1191_CR10","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/j.jacc.2005.09.042","volume":"47","author":"PJ Barter","year":"2006","unstructured":"Barter PJ and Kastelein JJ (2006) Targeting cholesteryl ester transfer protein for the prevention and management of cardiovascular disease. J Am Coll Cardiol 47: 492\u2013499","journal-title":"J Am Coll Cardiol"},{"key":"BFncpcardio1191_CR11","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1161\/01.RES.0000170946.56981.5c","volume":"96","author":"GF Lewis","year":"2005","unstructured":"Lewis GF and Rader DJ (2005) New insights into the regulation of HDL metabolism and reverse cholesterol transport. Circ Res 96: 1221\u20131232","journal-title":"Circ Res"},{"key":"BFncpcardio1191_CR12","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.1056\/NEJMoa0706628","volume":"357","author":"PJ Barter","year":"2007","unstructured":"Barter PJ  et al.; ILLUMINATE Investigators (2007) Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 357: 2109\u20132122","journal-title":"N Engl J Med"},{"key":"BFncpcardio1191_CR13","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1016\/j.pharmthera.2006.02.003","volume":"111","author":"MJ Chapman","year":"2006","unstructured":"Chapman MJ (2006) Therapeutic elevation of HDL-cholesterol to prevent atherosclerosis and coronary heart disease. Pharmacol Ther 111: 893\u2013908","journal-title":"Pharmacol Ther"},{"key":"BFncpcardio1191_CR14","doi-asserted-by":"publisher","first-page":"2180","DOI":"10.1056\/NEJMe0707210","volume":"357","author":"DJ Rader","year":"2007","unstructured":"Rader DJ (2007) Illuminating HDL\u2014is it still a viable therapeutic target? N Engl J Med 357: 2180\u20132183","journal-title":"N Engl J Med"},{"key":"BFncpcardio1191_CR15","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1161\/01.ATV.14.5.679","volume":"14","author":"M Gu\u00e9rin","year":"1994","unstructured":"Gu\u00e9rin M  et al. (1994) Preferential cholesteryl ester acceptors among the LDL subspecies of subjects with familial hypercholesterolemia. Arterioscler Thromb 14: 679\u2013685","journal-title":"Arterioscler Thromb"},{"key":"BFncpcardio1191_CR16","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1161\/01.ATV.0000219695.84644.56","volume":"26","author":"JS Millar","year":"2006","unstructured":"Millar JS  et al. (2006) Effects of the cholesteryl ester transfer protein inhibitor torcetrapib on apolipoprotein B100 metabolism in humans. Arterioscler Thromb Vasc Biol 26: 1350\u20131356","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"BFncpcardio1191_CR17","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1161\/ATVBAHA.107.151688","volume":"28","author":"M Gu\u00e9rin","year":"2008","unstructured":"Gu\u00e9rin M  et al. (2008) Inhibition of CETP by torcetrapib attenuates the atherogenicity of postprandial TG-rich lipoproteins in type IIB hyperlipidemia. Arterioscler Thromb Vasc Biol 28: 148\u2013154","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"BFncpcardio1191_CR18","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1161\/01.ATV.0000161928.16334.dd","volume":"25","author":"ME Brousseau","year":"2005","unstructured":"Brousseau ME  et al. (2005) Effects of cholesteryl ester transfer protein inhibition on high-density lipoprotein subspecies, apolipoprotein A-I metabolism, and fecal sterol excretion. Arterioscler Thromb Vasc Biol 25: 1057\u20131064","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"BFncpcardio1191_CR19","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1161\/ATVBAHA.106.138347","volume":"27","author":"L Yvan-Charvet","year":"2007","unstructured":"Yvan-Charvet L  et al. (2007) Inhibition of cholesteryl ester transfer protein by torcetrapib modestly increases macrophage cholesterol efflux to HDL. Arterioscler Thromb Vasc Biol 27: 1132\u20131138","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"BFncpcardio1191_CR20","doi-asserted-by":"publisher","first-page":"12448","DOI":"10.1074\/jbc.M311718200","volume":"279","author":"ST Thuahnai","year":"2004","unstructured":"Thuahnai ST  et al. (2004) Scavenger receptor class B type I-mediated cholesteryl ester-selective uptake and efflux of unesterified cholesterol: influence of high density lipoprotein size and structure. J Biol Chem 279: 12448\u201312455","journal-title":"J Biol Chem"},{"key":"BFncpcardio1191_CR21","doi-asserted-by":"publisher","first-page":"7527","DOI":"10.1021\/bi026949a","volume":"42","author":"D Rhainds","year":"2003","unstructured":"Rhainds D  et al. (2003) The role of human and mouse hepatic scavenger receptor class B type I (SR-BI) in the selective uptake of low-density lipoprotein-cholesteryl esters. Biochemistry 42: 7527\u20137538","journal-title":"Biochemistry"},{"key":"BFncpcardio1191_CR22","doi-asserted-by":"publisher","first-page":"4804","DOI":"10.1074\/jbc.M008725200","volume":"276","author":"DJ Greene","year":"2001","unstructured":"Greene DJ  et al. (2001) Elevated triglyceride content diminishes the capacity of high density lipoprotein to deliver cholesteryl esters via the scavenger receptor class B type I (SR-BI). J Biol Chem 276: 4804\u20134811","journal-title":"J Biol Chem"},{"key":"BFncpcardio1191_CR23","doi-asserted-by":"publisher","first-page":"1620","DOI":"10.1056\/NEJMoa071359","volume":"356","author":"JJ Kastelein","year":"2007","unstructured":"Kastelein JJ  et al.; RADIANCE 1 Investigators (2007) Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. N Engl J Med 356: 1620\u20131630","journal-title":"N Engl J Med"},{"key":"BFncpcardio1191_CR24","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1056\/NEJMoa070635","volume":"356","author":"SE Nissen","year":"2007","unstructured":"Nissen SE  et al.; ILLUSTRATE Investigators (2007) Effect of torcetrapib on the progression of coronary atherosclerosis. N Engl J Med 356: 1304\u20131316","journal-title":"N Engl J Med"},{"issue":"Suppl 16","key":"BFncpcardio1191_CR25","first-page":"II","volume":"116","author":"SJ Nicholls","year":"2007","unstructured":"Nicholls SJ  et al. (2007) Changes in levels of high density lipoprotein cholesterol predict the impact of torcetrapib on progression of coronary atherosclerosis: insights from ILLUSTRATE [abstract 684]. Circulation 116 (Suppl 16): II\u2013127","journal-title":"Circulation"},{"key":"BFncpcardio1191_CR26","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1161\/01.CIR.60.3.473","volume":"60","author":"DB Zilversmit","year":"1979","unstructured":"Zilversmit DB (1979) Atherogenesis: a postprandial phenomenon. Circulation 60: 473\u2013485","journal-title":"Circulation"},{"key":"BFncpcardio1191_CR27","doi-asserted-by":"publisher","first-page":"2474","DOI":"10.1161\/01.ATV.19.10.2474","volume":"19","author":"JS Cohn","year":"1999","unstructured":"Cohn JS  et al. (1999) Detection, quantification, and characterization of potentially atherogenic triglyceride-rich remnant lipoproteins. Arterioscler Thromb Vasc Biol 19: 2474\u20132486","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"BFncpcardio1191_CR28","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1194\/jlr.M200135-JLR200","volume":"43","author":"M Gu\u00e9rin","year":"2002","unstructured":"Gu\u00e9rin M  et al. (2002) Cholesteryl ester flux from HDL to VLDL-1 is preferentially enhanced in type IIB hyperlipidemia in the postprandial state. J Lipid Res 43: 1652\u20131660","journal-title":"J Lipid Res"},{"key":"BFncpcardio1191_CR29","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1172\/JCI26206","volume":"117","author":"T Vaisar","year":"2007","unstructured":"Vaisar T  et al. (2007) Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDL. J Clin Invest 117: 746\u2013756","journal-title":"J Clin Invest"},{"key":"BFncpcardio1191_CR30","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1016\/j.jacc.2007.10.033","volume":"51","author":"J Genest","year":"2008","unstructured":"Genest J (2008) The yin and yang of high-density lipoprotein cholesterol. J Am Coll Cardiol 51: 643\u2013644","journal-title":"J Am Coll Cardiol"},{"key":"BFncpcardio1191_CR31","doi-asserted-by":"publisher","first-page":"1907","DOI":"10.1016\/S0140-6736(07)61813-3","volume":"370","author":"R Krishna","year":"2007","unstructured":"Krishna R  et al. (2007) Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidaemia and on 24-h ambulatory blood pressure in healthy individuals: two double-blind, randomised placebo-controlled phase I studies. Lancet 370: 1907\u20131914","journal-title":"Lancet"},{"key":"BFncpcardio1191_CR32","doi-asserted-by":"publisher","first-page":"640","DOI":"10.7326\/0003-4819-146-9-200705010-00007","volume":"146","author":"WA van der Steeg","year":"2007","unstructured":"van der Steeg WA  et al. (2007) Role of the apolipoprotein B-apolipoprotein A-I ratio in cardiovascular risk assessment: a case-control analysis in EPIC-Norfolk. Ann Intern Med 146: 640\u2013648","journal-title":"Ann Intern Med"},{"key":"BFncpcardio1191_CR33","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1097\/HCO.0b013e3281bd8849","volume":"22","author":"G Walldius","year":"2007","unstructured":"Walldius G and Jungner I (2007) Apolipoprotein A-I versus HDL cholesterol in the prediction of risk for myocardial infarction and stroke. Curr Opin Cardiol 22: 359\u2013367","journal-title":"Curr Opin Cardiol"},{"key":"BFncpcardio1191_CR34","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1001\/jama.298.7.776","volume":"298","author":"E Ingelsson","year":"2007","unstructured":"Ingelsson E  et al. (2007) Clinical utility of different lipid measures for prediction of coronary heart disease in men and women. JAMA 298: 776\u2013785","journal-title":"JAMA"},{"key":"BFncpcardio1191_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.carrev.2007.01.003","volume":"8","author":"KE Watson","year":"2007","unstructured":"Watson KE  et al. (2007) HDL function as a target of lipid-modifying therapy. Rev Cardiovasc Med 8: 1\u20138","journal-title":"Rev Cardiovasc Med"},{"key":"BFncpcardio1191_CR36","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s11892-008-0010-5","volume":"8","author":"A Kontush","year":"2008","unstructured":"Kontush A and Chapman MJ (2008) Why is HDL functionally deficient in Type 2 diabetes? Curr Diabetes Rep 8: 51\u201359","journal-title":"Curr Diabetes Rep"},{"key":"BFncpcardio1191_CR37","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1038\/sj.clpt.6100180","volume":"81","author":"E Lai","year":"2007","unstructured":"Lai E  et al. (2007) Suppression of niacin-induced vasodilation with an antagonist to prostaglandin D2 receptor subtype 1. Clin Pharmacol Ther 81: 849\u2013857","journal-title":"Clin Pharmacol Ther"},{"key":"BFncpcardio1191_CR38","doi-asserted-by":"publisher","first-page":"S53","DOI":"10.1016\/j.amjcard.2007.09.080","volume":"100","author":"VS Kamanna","year":"2007","unstructured":"Kamanna VS and Kashyap ML (2007) Nicotinic acid (niacin) receptor agonists: will they be useful therapeutic agents? Am J Cardiol 100: S53\u2013S61","journal-title":"Am J Cardiol"},{"key":"BFncpcardio1191_CR39","doi-asserted-by":"crossref","unstructured":"Sviridov D  et al. (2007) Indices of reverse cholesterol transport in subjects with metabolic syndrome after treatment with rosuvastatin. Atherosclerosis [10.1016\/j.atherosclerosis.2007.07.007]","DOI":"10.1016\/j.atherosclerosis.2007.07.007"},{"key":"BFncpcardio1191_CR40","first-page":"1459","volume":"34","author":"C Charles-Schoeman","year":"2007","unstructured":"Charles-Schoeman C  et al. (2007) Effects of high-dose atorvastatin on antiinflammatory properties of high density lipoprotein in patients with rheumatoid arthritis: a pilot study. J Rheumatol 34: 1459\u20131464","journal-title":"J Rheumatol"}],"container-title":["Nature Clinical Practice Cardiovascular Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/ncpcardio1191.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/ncpcardio1191","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/ncpcardio1191.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T19:44:32Z","timestamp":1684439072000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/ncpcardio1191"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,4,22]]},"references-count":40,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2008,6]]}},"alternative-id":["BFncpcardio1191"],"URL":"https:\/\/doi.org\/10.1038\/ncpcardio1191","relation":{},"ISSN":["1743-4297","1743-4300"],"issn-type":[{"value":"1743-4297","type":"print"},{"value":"1743-4300","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,4,22]]}}}